Myovant Sciences Market Cap 2017-2022 | MYOV

Myovant Sciences market cap history and chart from 2017 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Myovant Sciences market cap as of January 27, 2023 is $2.61B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.614B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.040B 9.40
GSK (GSK) United Kingdom $72.263B 9.00
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.195B 19.11
Ginkgo Bioworks Holdings (DNA) United States $3.764B 0.00
Arcus Biosciences (RCUS) United States $1.675B 25.14
Biohaven (BHVN) United States $1.282B 0.00
Emergent Biosolutions (EBS) United States $0.672B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.388B 0.00
Ambrx Biopharma (AMAM) United States $0.075B 0.00
Enzo Biochem (ENZ) United States $0.069B 0.00
Gelesis Holdings (GLS) United States $0.026B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00